Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease

Mikolajczyk, Adam E.; Aronsohn, Andrew

doi:10.1053/j.ackd.2015.06.008

Cited by 6 publications

(6 citation statements)

References 80 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the currently widespread use of oral direct-acting antiviral agents (DAAs) in clinical practice, few studies have been conducted on the efficacy of DAAs in HCV-infected patients with CKD, resulting in mixed conclusions on the treatment of these patients. [13] HCV infection and other diseases In addition to diabetes and kidney diseases, the concomitant extrahepatic manifestations of HCV infection also include thyroid disease and haematological diseases. In recent years, more and more attention has been drawn to the increased risk of morbidity and mortality of cardiovascular diseases, secondary to atherosclerosis caused by HCV infection.…”

Section: Hcv Infection and Diabetes Mellitusmentioning

confidence: 99%

Diagnosis and treatment of chronic hepatitis C with concomitant extrahepatic manifestations deserves a closer look

Dou

Han

2017

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Section: Hcv Infection and Diabetes Mellitusmentioning

confidence: 99%

Diagnosis and treatment of chronic hepatitis C with concomitant extrahepatic manifestations deserves a closer look

Dou

Han

2017

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

“…Hepatitis C virus (HCV) infection poses a significant global health challenge, especially in low‐ and middle‐income countries. 1 , 2 Left untreated, ~ 50% of individuals infected with HCV will develop chronic hepatitis, cirrhosis, or hepatocellular carcinoma. 3 Patients with end‐stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis face a higher risk of HCV infection and transmission within dialysis units.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection

Chariyavilaskul,

Prompila,

Wittayalertpanya

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

Sofosbuvir/Velpatasvir (SOF/VEL) is a combination drug used for chronic hepatitis C (HCV) infection. However, limited information exists regarding the pharmacokinetics of SOF/VEL and its metabolites in hemodialysis patients. We conducted a prospective investigation of the pharmacokinetic parameters of SOF/VEL after a single dose of SOF/VEL (400/100 mg) on days with and without dialysis in 12 Thai hemodialysis patients with chronic HCV infection, who had been undergoing hemodialysis for a duration of 0.5–20 years. Blood samples were collected before dose (0) and 0.5, 1.0, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, and 12.0 h after dose. Dialysate samples were also collected before dose (0) and 1.0, 2.0, 3.0, and 4.0 h after dose. Plasma and dialysate samples were quantified for SOF and its metabolite, GS‐331007, and VEL concentrations using a fully validated LCMS technique. In addition, a preliminary efficacy study was conducted using the proposed SOF/VEL dose reduction regimen in all patients. No differences in SOF/VEL PK parameters between on‐ and off‐dialysis studies. On the contrary, GS‐331007 exhibited a 30% reduction in the area under the plasma concentration–time curve from time 0 to 24 h (AUC0‐24h) on dialysis days compared with non‐dialysis days (AUC0‐24h ratio 0.68 vs. 1.04, respectively). The dialysis clearance of SOF and GS‐331007 was 9.35 (8.72–15.11) and 8.89 (8.52–14.07) mL/min, respectively. Subsequently, an alternate‐day regimen of SOF/VEL (400/100 mg) was administered for 12 weeks, resulting in an undetectable plasma HCV viral load without side effects. Further clinical studies are warranted to validate the efficacy and safety of our proposed dose reduction regimen.

show abstract

“…Medical options for the treatment of CHB generally range from the injected form of interferon- α to the oral forms of nucleoside analogs (NAs). NAs used in the treatment of CHB patients are generally considered effective and convenient due to their oral administration and aside from telbivudine, exhibit minimal negative effects on renal function [7, 8]. However, with progression to CKD, interferon- α is not suitable due to poor tolerance, injection risks, and low effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Chang

Lin

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a serious complication affecting patients with chronic hepatitis. The effectiveness of CHM for the prevention of CKD in hepatitis patients remains unclear. Therefore, we conducted a retrospective cohort study to investigate the effectiveness of CHM in preventing the development of CKD in hepatitis patients. From a subdataset of the Taiwan National Health Insurance Research Database (NHIRD), we included 19,409 patients newly diagnosed with hepatitis B and hepatitis C between the years 2000 and 2010. After exclusion criteria and 1 : 1 propensity score matching process, we compared demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts. Statistical analysis was applied to evaluate the differences in characteristic distributions and to compare the cumulative incidence of CKD between the CHM and non-CHM cohorts. This study showed that the patients suffering from hepatitis C with CHM treatment more than 90 days as an adjuvant therapy combined with western medical treatment modalities exhibited a decreased risk of developing CKD (hazard ratio (HR) = 0.40, 95% confidence interval (CI) = 0.21–0.76, p value <0.01). The Kaplan–Meier curve revealed a lower cumulative incidence rate of CKD (p value = 0.004) for the CHM cohort. For further reference, we herein offer the ten most frequently prescribed single herbs and herbal formulas; as such, Salviae miltiorrhizae and Jia-Wei-Xiao-Yao-San were the most commonly prescribed single herb and formula, respectively. This nationwide retrospective cohort study provides evidence that CHM is an effective adjuvant treatment to decrease the risk of developing CKD in hepatitis C patients.

show abstract

Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease

Cited by 6 publications

References 80 publications

Diagnosis and treatment of chronic hepatitis C with concomitant extrahepatic manifestations deserves a closer look

Diagnosis and treatment of chronic hepatitis C with concomitant extrahepatic manifestations deserves a closer look

Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Contact Info

Product

Resources

About